Preclinical and clinical studies have now demonstrated resistance mutations in patients with FLT3–ITD AML treated with quizartinib, particularly the F691L gatekeeper and D835/I836 activation loop mutations (83, 84). This evidence concerns the gene FLT3 and acute myeloid leukemia.